Halozyme's PEGPH20 leads to worse OS in first-line pancreatic cancer

Halozyme Therapeutics Inc. (NASDAQ:HALO) reported that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat previously untreated

Read the full 319 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE